摘要
目的:探讨程序性细胞死亡蛋白1(PD-1)和程序性细胞死亡配体1(PD-L1)研究的热点现状和未来前景。方法:以Scopus为数据源,系统检索与分析从建库至2021年12月31日收录的PD-1/PD-L1抑制剂在癌症治疗领域研究应用的相关文献。使用基于R语言的Bibliometrix程序和VOS viewer统计分析软件对相关纳入文献进行计量学可视化分析。分别对主题词进行词云分析、聚类分析、聚类树状分析和爆发监测等,并对共被引期刊和代表性高被引文章进行分析。结果:共纳入分析6954篇PD-1和PD-L1在癌症领域研究相关的文章。自2015年出版物数量快速增长,2015-2022年发表的相关文章占所有发文量的97.43%。N Engl J Med、J Clinin Oncol和Clin Cancer Res等是被共同引用最多的期刊。研究热点包括各种肿瘤在使用PD-1和/或PD-L1抑制剂治疗后的疗效和预后,以及针对肿瘤的重要免疫因子的激活或表达。结论:PD-1和PD-L1研究在2014年后显著增加,不断有新的PD-1/PD-L1抑制剂药物被研发用于治疗癌症,现有药物也在不断拓展适应证治疗不同癌症。各种肿瘤经PD-1/PD-L1抑制剂治疗后的疗效和预后,以及抗肿瘤免疫过程中重要因子的激活或表达将仍是目前研究的主要热点。
Objective:To explore the current status and future prospects of programmed cell death protein 1(PD-1)and programmed cell death ligand 1(PD-L1)research.Methods:The abstracts and citation database Scopus was used as the data source to systematically search and analyze the relevant literatures on the research and application of PD-1/PD-L1 inhibitors in the field of cancer treatment from the establishment of the database to December 31,2021.The bibliometrix program based on R language and the VOS viewer statistical analysis software were used to carry out quantitative visualization analysis of relevant included literatures.Word cloud analysis,cluster analysis,cluster tree analysis,outbreak monitoring,etc.were performed on subject headings,and co-cited journals and representative high-cited articles were analyzed.Results:A total of 6954 articles related to PD-1 and PD-L1 in cancer research were included and analyzed.Related articles published from 2015 to 2022 accounted for 97.43%of all published articles.N Engl J Med,J Clinin Oncol and Clin Cancer Res are among the most co-cited journals.The main research hotspots include the efficacy and prognosis of various tumors after treatment with PD-1 and/or PD-L1 inhibitors,as well as the activation or expression of important tumor-targeted immune factors.Conclusion:The research on PD-1 and PD-L1 has increased significantly after 2014,and new PD-1/PD-L1 inhibitor drugs are constantly being developed for the treatment of cancer,and existing drugs are constantly expanding their indications to treat different cancers.The efficacy and prognosis of various tumors treated with PD-1/PD-L1 inhibitors,as well as the activation or expression of important factors in the process of anti-tumor immunity,will remain the focus of current research.
作者
王娜
田金徽
WANG Na;TIAN Jin-hui(Zhengzhou Central Hospital Affiliated to Zhengzhou University,Henan Zhengzhou 450007,China;Evidence-Based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Gansu Lanzhou 730000,China)
出处
《中国药物评价》
2022年第3期241-247,共7页
Chinese Journal of Drug Evaluation
